Amyotrophic Lateral Sclerosis
Conditions
Brief summary
This Phase 1 randomized, placebo-controlled, double-blind study will evaluate the PK/PD relationship of single doses of QRL-101 in 12 ALS participants. The study will also assess safety and tolerability in participants receiving either QRL-101 or placebo.
Detailed description
This is a randomized, placebo-controlled, double-blind, single-dose, single-site, Phase 1 study to explore the pharmacokinetics (PK) and pharmacodynamics (PD) of single doses of QRL-101 in participants with ALS. In addition, the safety and tolerability of QRL-101 will be evaluated. Single doses of QRL-101 or placebo will be administered as an oral liquid to approximately 12 participants with ALS. The study will explore the PK, PD, and PK/PD relationship among three dose levels of QRL-101 and placebo. The randomization will be 1:1:1:1 for the four study groups and will be conducted in 3 blocks (cohorts) of 4, where participants will be randomized 3:1 (QRL-101:placebo) for increasing dose levels of QRL-101.
Interventions
DRUGQRL-101
Single doses of QRL-101 will be orally administered. The dose levels may change subject to available nonclinical, clinical, safety, and PK data.
OTHERPlacebo
Single doses of compartor placebo will be orally administered. The dose levels may change subject to available nonclinical, clinical, safety, and PK data.
Sponsors
QurAlis Corporation
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Age 18 to 80 years of age inclusive at the time of signing the informed consent. 2. Diagnosis of ALS, by either Gold Coast Criteria or El Escorial Criteria (possible, probable laboratory supported, probable, or definite) 3. Clinical chemistry laboratory values within acceptable range for the population, as per investigator judgment. 4. Body mass index of 18 to 32 kg/m2 (inclusive). 5. Willing and able to practice effective contraception.
Exclusion criteria
1. Currently enrolled in any other clinical trial involving a study drug, off-label drug or device use, or any other type of medical research judged not scientifically or medically compatible with this study. 2. History or presence of medical illness including, but not limited to, any cardiovascular, hepatic, respiratory, hematological, endocrine, psychiatric, or neurological disease, convulsions, or any clinically significant laboratory abnormality that, in the judgment of the investigator, indicate a medical problem that would preclude study participation. 3. Off-label use of drugs or devices that are being used or investigated as disease-modifying therapies in ALS 4. Participated in another clinical study within 30 days, or 5 half-lives of the previous investigational product, whichever is greater, prior to the planned randomization date. 5. Taking any prescription or nonprescription medicines that are cytochrome P450 3A4 inducers, inhibitors, or substrates within 30 days or 5 half-lives, whichever is greater, prior to the planned randomization date
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| QRL-101 plasma concentration | Baseline through Follow up (Day 10) |
| PK/PD Relationship: Strength-Duration Time Constant (SDTC) | Baseline through Follow up (Day 10) |
Secondary
| Measure | Time frame |
|---|---|
| Plasma PK profile: Maximum concentration observed (Cmax) | Baseline through Follow up (Day 10) |
| Safety and Tolerability: Adverse Events (AEs) | Baseline through Follow up (Day 10) |
| Plasma PK profile: Area under the concentration time curve from time 0 to 24 hours (AUC0-24hr) | Baseline through Follow up (Day 10) |
| Plasma PK profile: Time of maximum drug concentration (Tmax) | Baseline through Follow up (Day 10) |
| Safety and Tolerability: Serious Adverse Events (SAEs) | Baseline through Follow up (Day 10) |
Countries
Netherlands
Outcome results
None listed